Login to Your Account

Medicinova gains foothold in NASH dash with fast track designation

By Michael Fitzhugh
Staff Writer

Thursday, April 16, 2015

New FDA fast track status for Medicinova Inc.'s phase II nonalcoholic steatohepatitis (NASH) drug MN-001 (tipelukast) invigorated the company's U.S.-listed shares (NASDAQ:MNOV), pushing them 41.3 percent higher to $4.96 in heavy trading Thursday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription